CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 2, 1997, Pages 240-249

  Rebello, Sam S ^a   Miller, Bernard V ^a   Basler, Geoffrey C ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antithrombin; Antithrombotic; Arterial thrombosis; Electrolytic injury; Platelets; Venous thrombosis

Indexed keywords

CVS 1123; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD VESSEL INJURY; CAROTID ARTERY; DOSE RESPONSE; DRUG EFFECT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; JUGULAR VEIN; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION INHIBITION; VEIN THROMBOSIS;

ANIMALS; ANTITHROMBIN III; ANTITHROMBINS; ARTERIAL OCCLUSIVE DISEASES; BLOOD COAGULATION; DOGS; FEMALE; MALE; OLIGOPEPTIDES; PEPTIDE HYDROLASES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOPHLEBITIS; THROMBOSIS;

EID: 0031025330     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199702000-00013     Document Type: Article

References (40)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: interaction, maintenance and regulation. Biochemistry 1991;30:10363-70.
2. Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin and calcium chelation. Blood 1991;78:423-34.
3. Coughlin SR. Thrombin receptor function and cardiovascular disease. Trends Cardiovasc Med 1994;4:77-83.
4. Hilpert K, Ackermann J, Banner DW, et al. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem 1994;37:3889-901.
5. Davey M, Luscher E. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 1967;216:857-8.
6. Fenton JW. Regulation of thrombin generation and functions. Semin Thromb Hemost 1988;14:234-40.
7. Coughlin SR, Vu T-KH, Hung DT, Wheaton VI. Characterization of the cloned platelet thrombin receptor: issues and opportunities. J Clin Invest 1992;89:351-5.
8. Graham DJ, Alexander JJ. The effects of thrombin on bovine aortic endothelial and smooth muscle cells. J Vasc Surg 1990;11:307-13.
9. Haver VM, Namm DH. Characterization of the thrombin-induced contraction of vascular smooth muscle. Blood Vessels 1984;21: 53-63.
10. Walz DA, Anderson GF, Fenton JW. Responses of aortic smooth muscles to thrombin and thrombin analogues. Ann N Y Acad Sci 1986;485:323-32.
11. Jungi TW, Spycher MO, Nydegger UE, Barandum S. Platelet-leukocyte interaction: selective binding of thrombin-stimulated platelets to human monocytes, polymorphonuclear leukocytes, and related cell lines. Blood 1986;67:629-36.
12. Weksler BB, Ley CW, Jaffe EA. Stimulation of endothelial cell prostacyclin by thrombin, trypsin, and the ionophore A23187. J Clin Invest 1982;62:923-30.
13. Prescott SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor when stimulated by thrombin. Proc Natl Acad Sci U S A 1984;81:3534-8.
14. Camps M, Carozzi A, Schnabel P, Scheer A, Parker PJ, Gierschik P. Isozyme-selective stimulation of phospholipase C-β2 by G protein βτ-subunits. Nature 1992;360:684-6.
15. Daniel TO, Gibbs VC, Milfay DF, Garavoy M, Williams LT. Thrombin stimulates c-sis gene expression in microvascular endothelial cells. J Biol Chem 1986;261:9579-82.
16. Chen LB, Buchanan JM. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci U S A 1975;72: 131-5.
17. Dohlman HG. Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem 1991;60:653-8.
18. Vu TH, Hung DT, Wheaton VT, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-68.
19. Hung DT, Vu TH, Nelken NA, Coughlin SR. Thrombin-induced events in non-platelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor. J Cell Biol 1992;116:827-32.
20. Scharfstein JS, Gold HK, Loscalzo J. New antithrombotic strategies. Thromb Hemorrh 1994;59:1207-23.
21. Yasuda T, Gold HK, Fallon JT, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988;81:1284-91.
22. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
23. Rote WR, Dempsey EM, Oldeschulte GL, et al. Evaluation of a novel orally active direct inhibitor of thrombin in animal models of thrombosis [Abstract]. Circulation 1994;901847.
24. Cousins GR, Friedrichs GS, Sudo Y, et al. Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious canine. Circulation 1996;94:1705-12.
25. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994;89:1802-9.
26. Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989;74:1181-95.
27. Ginsberg JS, Nurmohamed MT, Gent M, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994;90:2385-9.
28. Eriksson BI, Kalebo P, Ekman S, et al. Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994;72:227-31.
29. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res 1980; 17:841-53.
30. Mickelson JK, Simpson PJ, Lucchesi BR. Antiplatelet monoclonal F(ab′)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989;21:393-405.
31. Sudo Y, Kilgore KS, Lucchesi BR. Monoclonal antibody [7E3 F(ab′)2] prevents arterial but not venous rethrombosis. J Cardiovasc Pharmacol 1995;26:241-50.
32. Rote WE, Nedelman MA, Mu DX, et al. Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys. Stroke 1994;25: 1223-32.
33. Lucchesi BR, Rote WE, Driscoll EM, Mu DX. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist. Br J Pharmacol 1994;113:1333-43.
34. Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation 1990;82:169-77.
35. Werns SW, Rote WE, Davis JH, Guevara T, Lucchesi BR. Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis. Am Heart J 1994;127:727-37.
36. Lynch JJ Jr, Sitko GR, Mellott MJ, et al. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjuctive therapy: a comparison of factor Xa versus thrombin inhibition. Cardiovasc Res 1994;28:78-85.
37. 125I-thrombin binding by rabbit thoracic aorta in vitro. Thromb Haemost 1985;53:228-34.
38. Berg DT, Wiley MR, Grinnell BW. Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator. Science 1996;273:1389-91.
39. Callas D, Bacher P, Iqbal O, Hoppensteadt D, Fareed J. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res 1994;74:193-205.
40. Weitz J, Hirsh J. New anticoagulant strategies. J Lab Clin Med 1993;122:364-73.